ProMIS Neurosciences Taps Biogen Veteran as CCO Ahead of Key Alzheimer’s Trial Readout

  • ProMIS Neurosciences appointed Ivana Rubino, Ph.D., as Chief Commercial Officer effective October 5, 2026.
  • Dr. Rubino brings 15+ years of neuroscience and Alzheimer’s experience from Biogen and Roche.
  • ProMIS granted Dr. Rubino an inducement award of 80,000 stock options with a $9.37 exercise price.
  • PMN310’s 12-month topline data from the PRECISE-AD trial is expected in Q1 2027.

ProMIS’ appointment of Dr. Rubino underscores its push toward commercialization as it prepares for critical PMN310 data. The move reflects the growing competition in Alzheimer’s therapeutics, where Biogen and Eisai’s LEQEMBI has set a new benchmark. Dr. Rubino’s deep experience in launching and scaling neuroscience therapies positions ProMIS to navigate regulatory and market challenges ahead.

Commercialization Strategy
How Dr. Rubino’s experience with Biogen’s LEQEMBI will shape PMN310’s market access and payer planning.
Clinical Data Impact
Whether the 12-month topline data from the PRECISE-AD trial will meet expectations and support further development.
Pipeline Expansion
The pace at which ProMIS advances its broader neuroscience pipeline beyond Alzheimer’s.